← Back to Search

Dietary Supplement

Curcumin + Piperine for Cancer-Related Inflammation

Phase 1
Waitlist Available
Led By Aminah Jatoi, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient must have either a history of cancer or active cancer
Be older than 18 years old
Must not have
Taking any of the following drugs at the time of study participation: epidermal growth factor receptor inhibitor, topoisomerase 1 inhibitor (camptothecin, irinotecan); buspirone, benzodiazepines, zolpidem, calcium channel blockers (such as felodipine, nifedipine, verapamil); digoxin or quinidine; codeine or fentanyl; phenytoin, propranolol, rifampin, or theophylline
Active cholecystitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 month post-treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial studies the effects of curcumin and piperine in reducing inflammation and discomfort in older cancer patients with ureteral stents. Curcumin, found in turmeric, helps reduce inflammation, while piperine, found in black pepper, helps the body absorb more curcumin. The goal is to find the best dose that is safe and effective.

Who is the study for?
This trial is for older cancer patients with a ureteral stent who experience pain, spasms, or urgency. They must be able to swallow supplements, avoid grapefruit juice for the study duration, and provide urine samples. It's not suitable for those on warfarin, with active cholecystitis, needing certain anti-inflammatory drugs, or taking specific medications like benzodiazepines.
What is being tested?
The trial tests if curcumin (a spice) and piperine (from pepper), when taken together can reduce inflammation and discomfort caused by ureteral stents in cancer patients. The study will also determine the best dose of these substances and monitor their effects through questionnaires and urine tests.
What are the potential side effects?
Potential side effects may include digestive issues due to curcumin and piperine ingestion. Since this is a phase I trial determining the best dose, exact side effects are being studied but could involve stomach upset or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have or had cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking specific medications like EGFR inhibitors or calcium channel blockers.
Select...
I currently have gallbladder inflammation.
Select...
I need to take non-steroidal anti-inflammatory drugs that I can't stop for a week.
Select...
I am currently taking warfarin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 month post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 month post-treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Maximum tolerated dose (MTD) of curcumin in combination with piperine
Optimal biologically active dose for curcumin in combination with piperine extract (standardized)
Secondary study objectives
Change in quality of life (QOL) by means of the USSQ
Other study objectives
Change in prostaglandin E2 concentrations

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Supportive care (curcumin, piperine)Experimental Treatment4 Interventions
Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Curcumin
2017
Completed Phase 4
~1070

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common cancer treatments work through various mechanisms to target and eliminate cancer cells. Curcumin, a compound similar to turmeric, reduces inflammation by decreasing chemical mediators, which can help alleviate symptoms and potentially slow cancer progression. Piperine, derived from pepper, enhances the bioavailability of curcumin, making it more effective. Chemotherapy targets rapidly dividing cells, including cancer cells, but can also affect healthy cells, leading to side effects. Radiation therapy uses high-energy particles to damage the DNA of cancer cells, causing them to die. Immunotherapy boosts the body's immune system to recognize and attack cancer cells. Understanding these mechanisms is crucial for cancer patients as it helps in selecting the most appropriate treatment, managing side effects, and improving overall outcomes.
Dietary regulation of P-gp function and expression.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,473 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,906 Previous Clinical Trials
41,012,019 Total Patients Enrolled
Aminah Jatoi, M.D.Principal InvestigatorMayo Clinic
9 Previous Clinical Trials
352 Total Patients Enrolled

Media Library

Curcumin (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT02598726 — Phase 1
Cancer Research Study Groups: Supportive care (curcumin, piperine)
Cancer Clinical Trial 2023: Curcumin Highlights & Side Effects. Trial Name: NCT02598726 — Phase 1
Curcumin (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02598726 — Phase 1
~1 spots leftby Nov 2025